Replimune Group

REPL trading on NASDAQ since 2018

$7.15 (Δ -6.23%)
-$0.47 since open

Replimune Group is a biopharmaceutical company focused on developing cutting-edge cancer treatments using innovative immunotherapy approaches. **Step-by-Step Explanation:** 1. **Company Name:** Begin with "Replimune Group" as instructed. 2. **Industry Context:** Describe them as a biopharmaceutical company to set the industry context. 3. **Focus Area:** Mention their focus on developing cancer treatments, which is their main product area. 4. **Methodology:** Include that they use immunotherapy approaches to explain their method of treatment development. This sentence effectively conveys the necessary information in a clear and concise manner, adhering to all specified guidelines.

type open high low market
cap
volume
stock $6.42 $8.07 $5.71 $291.78M 202.08M
eps p/e p/s operating
margin
profit
margin
yield
-$0.79 n/a +Inf -Inf% -Inf% 0%